Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy.

导出 LinkOut

翻译打印收藏纠错

作者： Chiara,Sarlo ^[1] ; Francesco,Buccisano ; Luca,Maurillo ; Mariagiovanna,Cefalo ; Luigi,Di Caprio ; Laura,Cicconi ; Concetta,Ditto ; Licia,Ottaviani ; Ambra,Di Veroli ; Maria Ilaria,Del Principe ; Maria Assunta,Grasso ; Daniela,Nasso ; Giovanna,De Santis ; Sergio,Amadori ; Adriano,Venditti

作者单位： Department of Hematology, University of Rome Tor Vergata, Viale Oxford 81, 00133 Rome, Italy. ^[1]

DOI 10.1155/2013/705714

PMID 23738080

发布时间 2021-10-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览38

Leukemia research and treatment

2013年2013卷

705714页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy.

Leukemia research and treatment

相似文献

Leukemia research and treatment

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy.

Leukemia research and treatment

相似文献

Leukemia research and treatment

相关期刊

检索历史清除